Great news! I am thrilled to announce that Cardior successfully closed an oversubscribed €64 million Series B financing round. This significant support will accelerate Cardior’s pioneering path towards bringing transformative RNA-based therapeutics to patients suffering from cardiac diseases worldwide. I would like to thank the new investors INKEF Capital, FundPlus, Sunstone Partners, Hadean Ventures, and coparion as well as the existing ones for their continued support and trust in our innovative platform technology and experienced team.

https://www.linkedin.com/posts/claudia-ulbrich-708034b_financing-biotech-cardiacdisease-activity-6836237214767214592-ByRy

Ulbrich&Partner supported White & Case partner Dr. Sven-Holger Undritz in his capacity as insolvency administrator of Provecs Medical GmbH on the sale of the laboratory to Centogene AG.

=========================================================================================================================================================================================

Here is what White & Case said:

Hamburg – White & Case Partner Dr. Sven-Holger Undritz hat in seiner Eigenschaft als Insolvenzverwalter die Laboreinrichtung und -geräte der Provecs Medical GmbH (Provecs) an die CENTOGENE AG (CENTOGENE) veräußert. Auch nach der Stellung des Insolvenzantrags am 25.9.2019 beim Amtsgericht Hamburg wurde die Forschungs- und Entwicklungsarbeit der Provecs im Bereich neuartiger Immuntherapeutika für die Behandlung von Krebs zunächst vollumfänglich fortgeführt. Das Provecs-Team hat eine patentierte Plattformtechnologie entwickelt, die mit Hilfe optimierter Erkältungsviren (Adenoviren) Informationen in das Krebsgewebe bringen. Durch die rasante Ausbreitung der COVID-19-Pandemie verlagerte sich der Schwerpunkt des ursprünglich auf die patentierte Plattformtechnologie ausgerichteten Investorenprozesses, der von der auf die Biotech-Branche spezialisierten Unternehmensberatung Ulbrich & Partner aus Hannover begleitet wurde, schnell hin zu der Laboreinrichtung der Provecs, die teilweise auch für die COVID-19-Diagnostik einsatzfähig ist. Per sofort übernimmt CENTOGENE Laboreinrichtung und -geräte der Provecs an deren bisherigem Standort in Hamburg. Damit soll kurzfristig zunächst eine erhöhte Testkapazität für das COVID-19-Virus ermöglicht und darüber hinaus eine Erweiterung der Laborkapazitäten für die diagnostischen Tests auf seltene genetische Krankheiten geschaffen werden.

„Aufgrund der aktuellen Situation rund um die COVID-19-Pandemie bin ich sehr froh, dass wir aus dem Insolvenzverfahren heraus die Laborkapazitäten der Provecs zügig an CENTOGENE übertragen konnten“, kommentierte Insolvenzverwalter Dr. Sven-Holger Undritz die Transaktion.

CENTOGENE, mit Hauptsitz in Rostock, ist eines der weltweit größten Gentechnologie- und Biotech-Unternehmen und ein führender Anbieter von genetischen diagnostischen Analysen seltener Erbkrankheiten.

Zum White & Case Team um Partner Dr. Sven-Holger Undritz gehörten die Local Partner Dr. Ellen Meyer-Sommer und Béla Knof (alle Insolvenz/Restrukturierung, Hamburg). Unterstützt wird der Insolvenzverwalter von der auf die Biotech-Brache spezialisierten Unternehmensberatung Ulbrich & Partner aus Hannover.

For more details please follow the link: https://inso.whitecase.com/news/white-case-partner-dr-sven-holger-undritz-gelingt-verkauf-von-gentechnik-labor-der-provecs

Hanover, June 28, 2019 – ulbrich&partner advised the German biotech company MODAG on the in-licensing of novel chemical IP from Max Planck Innovation GmbH extending its compound portfolio targeting neurodegenerative diseases and on the closing of a € 12 million Series A financing round, led by the Massa Investment AG, Switzerland.

ulbrich&partner supported MODAG in business planning as well as advised on the structuring and operational implementation of the in-licensing of the active substance as well as the series A financing.

"With our long-term transaction experience and the sound know-how in financial and business planning we have been able to make a valuable contribution in this exciting Series A Financing as well as with regard to the in-licensing," comments Dr. Claudia Ulbrich, managing partner at ulbrich&partner in Hanover.

The MODAG GmbH, located at the high-technology park in Wendelsheim, Germany, deals with the research and development of therapeutics and diagnostics for neurodegenerative diseases. MODAG GmbH’s innovative approach offers a unique combination of early diagnosis and targeted disease modifying therapies.

Max Planck Innovation is responsible for the technology transfer of the Max Planck Society and, as such, serves as a link between industry and basic research. With its interdisciplinary team, it advises and supports scientists in evaluating their inventions, filing patents, and founding companies.

The team of ulbrich&partner advises regularly pharmaceutical and young biotech companies on business development and financing healthcare transactions.

Advisor to MODAG GmbH:

ulbrich&partner

Lead: Dr. Claudia Ulbrich (Managing Partner, Hanover)

Team: Andreas Kranzusch (Senior Consultant, Freiburg)

About ulbrich&partner:

ulbrich&partner Management Consulting is specializing in strategic and business consultancy with a focus on pharmaceutical, life science and health care technologies. As a team of experienced entrepreneurs and consultants along with a network of seasoned international experts u&p is ideally suited to provide with state-of-the-art solutions for consulting needs regarding structuring spin-offs, start-up funding and partnering & exit strategies.

ulbrich&partner is a management consultancy specialized in the high-tech & life science sector with special knowledge in the areas of consulting and the creation of business concepts, financing consulting including public funds, the filling of interim or management and corporate service positions as well as international business development, change management and transaction business.

Contact: Vanessa Krukenberg vanessa.krukenberg@ulbrichpartner.com Tel. 0511-37484051 / 0177-4634784

The founders team of Ycor reached the 3rd place in the Science4Life Venture Cup 2019.

The Ycor team has been coached by Dr. Claudia Ulbrich, founding partner of ulbrich&partner management consulting. The winner teams of this year’s Science4Lfe Venture Cup are presented here: https://youtu.be/oJRDrqW20rg

During the seminar topics will be handled as:

• Pitfalls when launching a biotech venture out of university, in-licensing IP and know-how from the tech transfer office, suitable deal terms with institutional VC investors, managing the conflict of interest of the spin-off as a university scientist and shareholder of the venture business.
• Accelerated exit by an structured M&A deal with big pharma – taking advantage of crossover financing – managing multiple tracks to secure funding – seamless work streams towards IPO or trade sale.

For further insights into the program please follow to this link:

To the official press release

Videoclips of the 5 main winners

To the event on High-Tech Gründerfonds homepage

To the official press release on cardior.de

To the event on High-Tech Gründerfonds homepage

To the official press release

Videoclips of the 5 main winners